GLP-1 AND GIP DUAL AGONISTS SHOW PROMISE GLP-1 and GIP dual agonists offer additional hepatic benefits by activating GIP receptors on adipocytes, promoting healthy adipose tissue expansion, increasing dietary lipid storage, and preventing lipid spillover to the liver
Look for the following in the report: Ingredient confirmed as semaglutide base Purity with impurities below 2% Potency matching your labeled dose A lot number tied to your specific batch Testing by an accredited lab (ISO 17025 preferred) You may want to use caution with a provider that cant or wont share which form of semaglutide they use, or if they wont share a CoA
The population included had a mean age ~50 years, with less than 30% having diabetes, GFR just under 60, and little albuminuria with median ACR being ~ 30 mg/g
Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation
But the medication can also curb food cravings and slow gastric emptying (the speed at which food leaves the stomach), which helps you feel fuller for longer
